Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population?

Sánchez, Miguel Castillo; Fàbregas-Escurriola, Mireia; Bergè-Baquero, Daniel; Fernández-SanMartín, MaIsabel; Goday-Arno, Albert

doi:10.1080/10641963.2016.1267200

Cited by 18 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antipsychotic-induced weight gain is a leading cause of noncompliance, leading to increased risk for relapse 3 , 4 . Moreover, obesity is also linked to greater morbidity, mortality, and decreased life expectancy due to an increased risk for cardiovascular and malignant disorders 5 – 8 . Being obese can affect psychological well-being, leading to lower quality of life 9 .…”

Section: Introductionmentioning

confidence: 99%

Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

Huang

et al. 2018

Transl Psychiatry

View full text Add to dashboard Cite

Antipsychotic pharmacotherapy is strongly obesogenic and is associated with increased oxidative stress in patients with schizophrenia. However, whether these changes reflect psychopathology, antipsychotic efficacy, or some other factor is not known. Our study aims to investigate the degree of oxidative stress in different BMI categories and to identify clinical symptomatology that may be paired with increased oxidative stress in a schizophrenia population. To this end, we performed a cross-sectional study and recruited 89 long-term inpatients with schizophrenia and collected the following variables: plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), routine biochemical analysis, and psychopathology through the Positive and Negative Syndrome Scale (PANSS). The results indicate that the levels of the lipid peroxidation product, MDA, were significantly higher in the high BMI group than the low (normal) BMI group. As expected, high BMI was associated with an atherogenic lipid profile; however, it was also associated with fewer psychopathological symptoms. Multiple regression analysis found that MDA levels, the PANSS general psychopathology subscore, and triglyceride levels (all p < 0.05) were independent contributors to the BMI in patients. These results suggested that oxidative stress may play an important role in antipsychotic-induced weight gain. Further investigations using the longitudinal design in first-episode schizophrenia patients are needed to explore the beneficial effect of antioxidants on the abnormal lipid metabolism mediated by antipsychotic treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

Huang

et al. 2018

Transl Psychiatry

View full text Add to dashboard Cite

show abstract

“…No presente estudo, todos os artigos analisados foram publicados no idioma inglês e em periódicos da área médica e da epidemiologia. A maioria dos estudos é originária dos Estados Unidos , da China [39][40][41][42][43][44][45][46] , da Espanha [47][48][49][50][51][52][53][54] , da Austrália [55][56][57][58] e da Inglaterra [59][60][61][62][63][64] . Os principais achados são em relação a alterações glicêmicas e lipídicas, síndrome metabólica, hipertensão, obesidade/ganho de peso e morbidade cardiovascular e serão detalhados em tópicos.…”

Section: Resultsunclassified

“…Oito artigos associaram a HAS com os fármacos utilizados para o tratamento da esquizofrenia 32,37,48,50,65,67,69,75 . A maior prevalência de HAS foi evidenciada por um estudo, assim como os menores índices de HDL-colesterol -fator protetivo às doenças cardiometabólicas 67 .…”

Section: Hipertensão Arterial Sistêmica (Has)unclassified

Doenças cardiovasculares e uso de antipsicóticos na esquizofrenia: uma revisão

Pscheidt

Zardeto

Sá

et al. 2022

J. bras. psiquiatr.

View full text Add to dashboard Cite

RESUMO Objetivo Realizar uma revisão de escopo a respeito dos efeitos adversos cardiovasculares e metabólicos associados ao uso de antipsicóticos em pessoas com o diagnóstico de esquizofrenia. Métodos Foi realizada uma revisão de escopo utilizando-se da base de dados PubMed, com descritores MeSH relacionados às doenças cardiovasculares e antipsicóticos. Foram encontrados 976 artigos, os quais foram filtrados por títulos, seguidos dos resumos e, na sequência, lidos na íntegra. Ao final, foram selecionados 71 artigos para a análise. Resultados O uso de antipsicóticos típicos e atípicos para tratamento da esquizofrenia associa-se a alterações glicêmicas e lipídicas, síndrome metabólica, hipertensão, ganho de peso e morbidade cardiovascular. Os estudos evidenciaram a existência de subdiagnóstico e subtratamento de doenças crônicas nessa população. A mortalidade por doença cardiovascular demonstrou aumento considerável nos pacientes em tratamento com agentes antipsicóticos, em comparação com a população geral. Conclusão Alguns fatores dos antipsicóticos, ainda não completamente determinados na psicofarmacologia, vêm se mostrando relacionados a maior risco de distúrbios metabólicos, comportamentais e intrínsecos às pessoas diagnosticadas com esquizofrenia, os quais podem agravar o curso clínico de tais doenças. Reconhece-se a necessidade de aprimorar o acompanhamento e o diagnóstico de doenças cardiovasculares e metabólicas entre pessoas com diagnóstico de esquizofrenia em tratamento com antipsicóticos típicos e atípicos.

show abstract

“…Primary care practitioners are ideally placed to screen for smoking and arrange appropriate treatment; however, studies have shown lower rates of screening in primary care for tobacco use in people with schizophrenia than in the general population. 10 …”

Section: Cardiometabolic Risk Factorsmentioning

confidence: 99%

Physical health monitoring for people with schizophrenia

Castle,

2023

Aust Prescr

View full text Add to dashboard Cite

Summary Schizophrenia is a severe psychiatric disorder associated with significant comorbidities and early mortality. People with schizophrenia have a greater predisposition to the top 6 modifiable global mortality (cardiometabolic) risk factors as defined by the World Health Organization (compared with the general population). These are driven by genetic, lifestyle and disease factors, and obesogenic antipsychotic medications. Smoking, obesity and type 2 diabetes are the most important modifiable cardiometabolic risk factors for cardiovascular disease in people with schizophrenia. Enhanced physical health screening, especially for cardiometabolic risk factors, is recommended for people with schizophrenia. A multidisciplinary holistic approach is recommended for treating people with schizophrenia, using contact with primary care practitioners to review their physical health.

show abstract

Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population?

Abstract: Schizophrenia (SZ); Treatment with antipsychotic drugs (TAD); Cardiovascular risk factor/s (CVRF); Without schizophrenia but on therapy with antipsychotic drugs (NS-TAD); Defined Daily Dose (DDD).

Cited by 18 publications

References 25 publications

Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients

Doenças cardiovasculares e uso de antipsicóticos na esquizofrenia: uma revisão

Physical health monitoring for people with schizophrenia

Contact Info

Product

Resources

About